Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;38(4):e70036.
doi: 10.1111/pcmr.70036.

YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma

Yan-Ling Zhou  1 , Xiao-Lian Liu  2   3 , Si-Si Huang  1 , Gui-Ming Zhang  1 , Xuan-Yu Jin  2   3 , Liang Chen  2   3 , Le Yu  1 , Yi-Lei Li  2   3
Affiliations

YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma

Yan-Ling Zhou et al. Pigment Cell Melanoma Res. 2025 Jul.

Abstract

BET inhibitors have the potential to treat malignant tumors via the epigenetic modification mechanism. Although BET inhibitors show promise as anticancer agents for uveal melanoma (UM), the emergence of acquired resistance significantly limits their clinical efficacy. We developed isogenic OTX015-resistant UM cell models (OMM2.3R and OMM2.5R) via exposure to escalating OTX015 concentrations (0.04-0.5 μM over 6 months). These resistant cells demonstrated reduced sensitivity to OTX015-induced cytotoxicity. Moreover, the migratory ability of resistant cells was less affected by OTX015 compared to parental cells. Transcriptome analysis revealed an upregulation of YAP-activated genes in resistant cells. Notably, OTX015-resistant cells retained sensitivity to YAP inhibition via shRNA or pharmacological inhibitors. This study establishes YAP activation as a novel compensatory mechanism driving BET inhibitor resistance in UM. These findings position YAP inhibition as a potential therapeutic target to overcome BET inhibitor resistance, with clinical translational potential for resistant UM patients.

Keywords: BET inhibitors; YAP; drug resistance; uveal melanoma; verteporfin.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Ambrosini, G., C. Do, B. Tycko, et al. 2019. “Inhibition of NF‐κB‐Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.” Cancer Research 79, no. 9: 2415–2425. https://doi.org/10.1158/0008‐5472.Can‐18‐3177.
    1. Baratta, M. G., A. C. Schinzel, Y. Zwang, et al. 2015. “An In‐Tumor Genetic Screen Reveals That the BET Bromodomain Protein, BRD4, Is a Potential Therapeutic Target in Ovarian Carcinoma.” Proceedings of the National Academy of Sciences of the United States of America 112, no. 1: 232–237. https://doi.org/10.1073/pnas.1422165112.
    1. Benedetti, R., and L. Altucci. 2019. “I BET on Anti‐FGFR to Fight Cancer Resistance.” EMBO Molecular Medicine 11, no. 2: 116. https://doi.org/10.15252/emmm.201810116.
    1. Braun, T., and C. Gardin. 2017. “Investigational BET Bromodomain Protein Inhibitors in Early Stage Clinical Trials for Acute Myelogenous Leukemia (AML).” Expert Opinion on Investigational Drugs 26, no. 7: 803–811. https://doi.org/10.1080/13543784.2017.1335711.
    1. Carvajal, R. D., G. K. Schwartz, H. Mann, I. Smith, and P. D. Nathan. 2015. “Study Design and Rationale for a Randomised, Placebo‐Controlled, Double‐Blind Study to Assess the Efficacy of Selumetinib (AZD6244; ARRY‐142886) in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma (SUMIT).” BMC Cancer 15: 467. https://doi.org/10.1186/s12885‐015‐1470‐z.

MeSH terms

LinkOut - more resources